타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Imdelltra (tarlatamab) | Tocilizumab | Ramucirumab | Blinatumomab | azacitidine |
Overview Company | Amgen | Roche / Genentech | Eli Lilly and Company | Amgen | Astellas Pharma Global Development, Inc. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | DLL3 × CD3 | Chronic Lymphocytic Leukemia | Non-Small Cell Lung Cancer | Precursor Cell Lymphoblastic Leukemia-Ly | Acute Myeloid Leukemia |
Overview Indication | Extensive-stage small cell lung cancer after platinum-based chemotherapy | Multiple Myeloma (MM); Multiple Myeloma Refractory | Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Leukemia; Myelodysplastic Syndrome |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | RECRUITING | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational | Investigational | Investigational |
Positioning Key differentiator | DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target. | novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity | novel 5-exo-miRNA panel for predicting response to second-line PTX plus RAM therapy in gastric cancer | novel mechanisms of action that traditional monoclonal antibodies cannot achieve | — |
Positioning Known limitation | Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion. | resistance to first- and second-line therapies | resistance to VEGFR2 blockade | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model | — |
Positioning Development positioning | 2L+ | — | — | — | — |
MoA Mechanism | Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity. | checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo | targets vascular endothelial growth factor receptor | targeting CD19/20/22 and engineered chimeric antigen receptor | CAR T cells sustained high levels of interferon-γ production, which induced immunogenic cell death in tumor cells and activated conventional dendritic cell |
MoA Biomarker | DLL3 expression by IHC is not required in the label but tracks with the biology. | biomarker for predicting treatment response in RA patients | biomarkers exist to predict therapeutic response | CD19 expression, whereas cytoplasmic CD22 expression | eGFR) of <60 mL/min exhibited significantly high |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | — | — | — | — |
Toxicology CRS | CRS ~51–55%, mostly grade 1–2 | — | — | — | — |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | — | — | — | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Imdelltra (tarlatamab) | Tocilizumab | Ramucirumab | Blinatumomab | azacitidine |
Overview Company | Amgen | Roche / Genentech | Eli Lilly and Company | Amgen | Astellas Pharma Global Development, Inc. |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | DLL3 × CD3 | Chronic Lymphocytic Leukemia | Non-Small Cell Lung Cancer | Precursor Cell Lymphoblastic Leukemia-Ly | Acute Myeloid Leukemia |
Overview Indication | Extensive-stage small cell lung cancer after platinum-based chemotherapy | Multiple Myeloma (MM); Multiple Myeloma Refractory | Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Leukemia; Myelodysplastic Syndrome |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | RECRUITING | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | Approved (flag incomplete) | Investigational | Investigational | Investigational |
Positioning Key differentiator | DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target. | novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity | novel 5-exo-miRNA panel for predicting response to second-line PTX plus RAM therapy in gastric cancer | novel mechanisms of action that traditional monoclonal antibodies cannot achieve | — |
Positioning Known limitation | Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion. | resistance to first- and second-line therapies | resistance to VEGFR2 blockade | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model | — |
Positioning Development positioning | 2L+ | — | — | — | — |
MoA Mechanism | Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity. | checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo | targets vascular endothelial growth factor receptor | targeting CD19/20/22 and engineered chimeric antigen receptor | CAR T cells sustained high levels of interferon-γ production, which induced immunogenic cell death in tumor cells and activated conventional dendritic cell |
MoA Biomarker | DLL3 expression by IHC is not required in the label but tracks with the biology. | biomarker for predicting treatment response in RA patients | biomarkers exist to predict therapeutic response | CD19 expression, whereas cytoplasmic CD22 expression | eGFR) of <60 mL/min exhibited significantly high |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | — | — | — | — |
Toxicology CRS | CRS ~51–55%, mostly grade 1–2 | — | — | — | — |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | — | — | — | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교